The American pharmaceutical giant Novavax has started developing a vaccine that will work better against the new virus variant omicron.
The vaccine against the new virus variant, which was first discovered in South Africa, should be ready for testing within a couple of weeks, a spokesperson told the news agency Reuters.
The news caused the company’s share price to rise by almost 9% on Friday.
Novavax’s coronary vaccine Nuvaxovid is approved in Indonesia and the Philippines. The company recently applied for EU approval, which means that Novavax could soon be the fifth manufacturer to have its COVID-19 vaccine approved in the EU.
Moderna states that since early 2021, the company has set up a strategy for predicting new virus variants.
“This strategy includes three levels of response if the current booster dose should prove to be insufficient against omicron,” Moderna stated.
Pfizer and BioNTech say that if the vaccines have no effect on a virus variant, they expect to be able to develop and produce a tailor-made vaccine against such a variant within about a hundred days, subject to the approval of the vaccine.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at email@example.com